Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
InterAct Therapeutics
Nashville, Tennessee, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
InterAct Therapeutics is a Nashville-based biotechnology company dedicated to discovering and developing small molecule inhibitors of protein-protein interactions (PPIs) for the treatment of cancer. The company was founded through a collaboration between Vanderbilt University and Deerfield Management to commercialize the pioneering research of Dr. Stephen Fesik. Its lead program focuses on disrupting the interaction between the MYC oncoprotein and its essential cofactor, WDR5, a strategy designed to inhibit MYC-driven tumor growth. InterAct leverages a structure-based drug discovery approach to target high-value, historically "undruggable" oncogenic drivers. By focusing on specific PPI interfaces, the company aims to create highly selective therapies for aggressive solid tumors and leukemias.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Vanderbilt UniversityDeerfield Management
Beyond the preview
Go deeper on InterAct Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InterAct Therapeutics.